Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Temporary Equity Common Stockholders' Equity (Deficit) (Unaudited)

v3.22.1
Condensed Consolidated Statements of Temporary Equity Common Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Temporary Equity [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Beginning balance at Dec. 31, 2020 $ 12,356 $ 16,651 $ 29,007 $ 1,514 $ (37,954)   $ (36,440)
Beginning balance, shares at Dec. 31, 2020 4,612,000 3,489,000   2,594,000        
Stock-based compensation 366   366
Exercise of stock options 4   $ 4
Exercise of stock options, shares                 29,916
Issuance of Incremental shares to StemoniX shareholders upon Merger  
Issuance of Incremental shares to StemoniX shareholders upon Merger, shares         805,000        
Net loss (7,366)   (7,366)
Issuance of Series C Convertible Preferred shares, net of issuance costs of $214 $ 1,786 1,786  
Issuance of Series C Convertible Preferred shares, net of issuance costs of $214, shares     567,000            
Issuance of Common Stock for acquisition consideration $ 2 59,918   59,920
Issuance of Common Stock for acquisition consideration, shares         11,007,000        
Conversion of Preferred Stock to Common Stock upon Merger $ (12,356) $ (16,651) $ (1,786) (30,793) $ 1 30,792   30,793
Conversion of preferred stock to common stock upon merger, shares (4,612,000) (3,489,000) (567,000)   11,197,000        
Conversion of 2020 Notes to Common Stock upon Merger 16,190   16,190
Conversion of 2020 convertible notes to common sock upon merger, shares         3,339,000        
Preferred stock warrant settled for Common Stock upon Merger  
Preferred stock warrant settled for Common Stock upon Merger , shares         43,000        
Warrant liability reclassified to equity upon Merger 421   421
Ending balance at Mar. 31, 2021 $ 3 109,205 (45,320)   63,888
Ending balance, shares at Mar. 31, 2021   28,985,000        
Beginning balance at Dec. 31, 2021 $ 3 110,174 (78,813) $ (74) 31,290
Beginning balance, shares at Dec. 31, 2021         28,993,000        
Stock-based compensation         334 334
Exercise of stock options         4   $ 4
Exercise of stock options, shares         5,000       5,174
Vesting of restricted stock        
Vesting of restricted stock, shares         8,000        
Issuance of Incremental shares to StemoniX shareholders upon Merger         (101) (101)
Issuance of Incremental shares to StemoniX shareholders upon Merger, shares         406,000        
Foreign currency translation adjustment         4 4
Net loss (9,163) (9,163)
Ending balance at Mar. 31, 2022 $ 3 $ 110,411 $ (87,976) $ (70) $ 22,368
Ending balance, shares at Mar. 31, 2022         29,412,000